• Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

  • Jul 16 2024
  • Length: 14 mins
  • Podcast

Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

Listen for free

View show details

  • Summary

  • Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia.

    Read the full article:
    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Show More Show Less
Physical Illness & Disease Hygiene & Healthy Living Biological Sciences
Show More Show Less
activate_samplebutton_t1

What listeners say about Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.